[Clinical studies on XXXX fine granules in the urological field].

@entity13507 @entity1 @entity294 @entity869 @entity35160 @entity7576 @entity5899 @entity2335 @entity293
Clinical studies of @entity7576 (SBTPC) fine granules, an oral antibiotic with @entity13507 linked @entity869 and beta-lactamase inhibitor, @entity5899 , were performed in acute uncomplicated @entity2335 and complicated @entity293 . 1. SBTPC fine granules were administrated at a dose of 187.5 mg 2-3 times daily for 5-7 days to 6 @entity1 with acute uncomplicated @entity2335 . Clinical efficacies as judged according to the criteria of the UTI Committee were excellent in 5 cases and moderate in 1 case with an effectiveness rate of 100%. All of 7 identified bacteria were eradicated by the treatment. 2. SBTPC fine granules were administrated at a dose of 187.5 mg or 375 mg 3 times daily for 5-7 days to 17 @entity1 with complicated @entity293 . Clinical efficacies as judged according to the criteria of the UTI Committee were excellent in 8 cases, moderate in 4 cases and poor in 5 cases with an effectiveness rate of 70.6%. Out of 17 identified bacteria, 14 (82.4%) were eradicated by the treatment. 3. As adverse reactions, @entity35160 , @entity294 and pharyngeal redness were observed in 1 case out of 31 cases treated with the drug. These symptoms, however, were mild and transient. No abnormal laboratory test values were observed. From the above results, it appears that SBTPC fine granules are useful in the treatment of @entity293 .
